David Graham

chief impact officer at NJoy LLC

David Graham is the chief impact officer at NJoy. He has over 27 years of experience in nicotine and non-nicotine new product development, tobacco control policy and related regulation in the international healthcare and vapor industries.

Graham’s career began with positions working with nicotine-replacement therapy and smoking cessation products in the U.K. in 1992 followed by international product and category development roles in Sweden. He then moved to the U.S. in 2000 to join Pharmacia, which subsequently became part of Pfizer, before joining Johnson & Johnson.

In 2013, he joined NJoy to lead the regulatory affairs function and prepare for regulation by the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

In addition to interacting with regulatory agencies, Graham co-led Njoy’s engagement with the National Institute of Drug Abuse to develop an electronic nicotine-delivery system (ENDS) for use for human subject research.

In 2016, Graham co-founded and became president of Reveritas Group, a consultancy of specialists and preferred providers formed to aid ENDS companies navigating the FDA’s premarket tobacco product application process via a total programming approach.